Dr. Reddy's Laboratories Launches India's First DCGI-Approved Semaglutide Injection 'Obeda ®' for Type 2 Diabetes
Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) announced the launch of its injectable semaglutide under the brand name Obeda®, marking an entry into the GLP-1 receptor agonists therapy space in India. The company received Drugs Controller General of India (DCGI) approval for generic semaglutide.The announcement underscores Dr. Reddy's readiness to serve unmet patient needs in India, addressing the country's significant diabetes burden, where over 101 million adults live with the condition.
In a Phase-III clinical study, Dr. Reddy's Obeda ® demonstrated non-inferior efficacy and similar safety to the innovator drug, exhibiting comparable glycaemic reduction.
The development of Obeda ® involved both API development and manufacturing, as well as formulation development conducted entirely in-house, highlighting Dr. Reddy’s capabilities in complex product development and peptide science.
Dr. Reddy's Obeda® semaglutide injection is available in 2 mg and 4 mg strengths, packaged in a pre-filled, disposable pen for once-a-week administration. Each pen delivers a minimum of 4 weekly doses, with a cost of INR 4,200 per month for both strengths.
As part of its phase-1 launch, Dr. Reddy’s aims to introduce generic semaglutide in several countries, subject to regulatory approval.
Erez Israeli, Chief Executive Officer of Dr. Reddy's, stated the launch reflects the company’s commitment to expanding access to advanced diabetes treatments.
M.V. Ramana, Chief Executive Officer, Branded Markets (India and Emerging Markets), noted that the launch strengthens the company’s diabetes portfolio and aims to improve long-term health outcomes for people living with chronic metabolic diseases.
Dr. Reddy's Obeda ® injection is accompanied by Sem aKare ™, a patient support programme featuring a digital app offering onboarding guidance, device training, and therapy adherence monitoring.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.